Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Inclusion Criteria: * A signed informed consent must be obtained prior to conducting any study-specific procedures * Histological or cytological confirmed advanced, metastatic, or progressive mismatch repair protein proficient (pMMR)/microsatellite stable (MSS) adenocarcinoma of colon or rectum * Microsatellite status should be performed per local standard of practice (e.g., immunohistochemistry \[IHC\] and/or polymerase chain reaction \[PCR\], or next-generation sequencing). Only participants with pMMR/MSS metastatic colorectal cancer (mCRC) are eligible * Known extended RAS and BRAF status as per local standard of practice * Participant must have progressed following exposure of all the following agents or below: * Prior exposure to the following: * Fluoropyrimidines (capecitabine or fluorouracil \[5-FU\]) * Irinotecan * Oxaliplatin * Anti-EGFR therapy if RAS and BRAF wild type with left colon primary * Patient must have evidence of progression on or after the last treatment regimen received and within 6 months prior to study enrollment * Patients who were intolerant to prior systemic chemotherapy regimens are eligible if there is documented evidence of clinically significant intolerance despite adequate supportive measures * Adjuvant/neoadjuvant chemotherapy can be considered as one line of chemotherapy for advanced/metastatic disease if the participant had disease recurrence within 6 months of completion * Eastern Cooperative Oncology Group (…